Mankind Pharma Q3 Results
- BSE: 543904
- NSE: MANKIND
- ISIN: INE634S01028
- Sector: Biotechnology & Drugs
BSE
2,086.50
26.95 (1.31%)
26.95 (1.31%)Volume4.99 K
Updated: Mon 9 Feb, 2026 | 15:29:18
NSE
2,083.3023.10 (1.12%)
23.10 (1.12%)Volume2.14 L
Updated: Mon 9 Feb, 2026 | 15:25:56
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q3 Results Highlights
- Total Income₹3,567.20 Cr.(10.44%)
- Operating Profit₹590.24 Cr.(-7.41%)
- Profit After Tax₹408.75 Cr.(7.50%)
- Operating Margin16.55%(-16.17%)
Note: Comparison is on YoY basis
Quarterly - Mankind Pharma Q3 Results
*All figures in crores except per share values
| Fiscal Period | Dec 25 | Sep 24 | QoQ Comp | Dec 23 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 2,976.96 | 2,314.73 | -0.69% | 2,110.18 | 14.83% |
| Depreciation/ Amortization | 222.60 | 100.49 | 0.35% | 109.73 | 15.76% |
| Operating Income | 590.24 | 746.70 | -15.62% | 496.78 | -7.41% |
| Net Income | 408.75 | 653.47 | -20.09% | 453.76 | 7.50% |
| Other Operating Expenses Total | 846.07 | 699.40 | -4.77% | 604.51 | 12.02% |
| Net Income Before Taxes | 509.00 | 851.23 | -18.43% | 562.33 | 2.35% |
| Total Revenue | 3,567.20 | 3,061.43 | -3.52% | 2,606.96 | 10.44% |
| Selling/ General/ Admin Expenses Total | 823.71 | 642.12 | -0.18% | 568.35 | 16.06% |
| Diluted Normalized EPS | 11.99 | 16.34 | -3.17% | 11.31 | 26.98% |